Collectively, these findings define an HDAC3–NRF2–GPX4 axis that suppresses ferroptosis in CRC, and highlight HDAC3 as a potential therapeutic target for ferroptosis-based cancer treatment. Here, GPX4 is linked to colorectal carcinoma.